Bupropion SR as an Anti-Craving Anti-Obesity Agent

安非他酮 SR 作为抗渴抗肥胖剂

• 批准号: 7231981
• 负责人: KRISTINE Jayne STEFFEN
• 金额: $ 5.4万
• 依托单位: SANFORD RESEARCH NORTH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7231981
• 关键词: Address; Adult; Adverse effects; Algorithms; Anti-Obesity Agents; Antidepressive Agents; Attenuated; Behavioral Mechanisms; Binge eating disorder; Body Weight decreased; Body mass index; Bupropion; Cessation of life; Clinical Research; Condition; Consumption; Coupled; Cues; Daily; Dopamine; Double-Blind Method; Eating; Eating Behavior; Equipment and supply inventories; Exhibits; Fellowship; Food; High Prevalence; Hour; Hunger; Incidence; Individual; Investigation; Laboratories; Measurement; Measures; Modality; Modification; Molecular; Names; Obesity; Outcome; Overweight; Pharmaceutical Preparations; Pharmacotherapy; Placebo Control; Placebos; Prevalence; Questionnaires; Rate; Reporting; Rewards; Risk; Role; Satiation; Slide; Stimulus; Testing; Therapeutic Intervention; Thinking; United States; United States National Institutes of Health; Week; Weight; clinical efficacy; craving; experience; feeding; food craving; hedonic; human subject; improved; insight; mortality; noradrenergic; obesity treatment; smoking cessation

DESCRIPTION (provided by applicant): As the prevalence of obesity increases and available pharmacotherapies remain of modest benefit, investigating the pharmacological modification of mechanisms that control food intake is imperative. Bupropion, an antidepressant and anti-craving agent for smoking cessation, has been observed to produce weight loss through an uncharacterized mechanism. The clinical efficacy of this compound is thought to result from noradrenergic and dopaminergic activity. Dopamine has an established role in modulating food reward. The objective of the proposed study is to test the primary hypothesis that bupropion will reduce food reward and craving in overweight and obese human subjects. To examine this postulate, a feeding laboratory paradigm, 72 hour dietary recall, and validated craving questionnaires will be used. Implications for the results of this study include providing insight into a potentially unique behavioral mechanism of action of the existing anorexigenic compound bupropion. Longer term implications for the results of this study include the potential investigation of this agent as a therapeutic intervention for conditions such as obesity and binge eating disorder.

描述（由申请方提供）：由于肥胖的患病率增加，可用的药物治疗仍然具有适度的益处，因此研究控制食物摄入的机制的药理学修饰是必要的。安非他酮是一种用于戒烟的抗抑郁剂和抗渴望剂，已观察到通过未表征的机制产生体重减轻。该化合物的临床疗效被认为是由去甲肾上腺素能和多巴胺能活性引起的。多巴胺在调节食物奖励中具有既定的作用。拟议研究的目的是检验安非他酮将减少超重和肥胖人类受试者的食物奖励和渴望的主要假设。为了检验这一假设，将使用喂养实验室范例、72小时饮食回忆和经验证的渴望问卷。这项研究的结果的影响，包括提供了一个潜在的独特的行为机制的行动，现有的抗氧化化合物安非他酮的洞察。这项研究结果的长期影响包括这种药物作为肥胖和暴食症等疾病的治疗干预的潜在研究。